Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETX 1153

Drug Profile

ETX 1153

Alternative Names: Amersib; Clostriban; eTS1153; ETX1153; ETX1153a; ETX1153b; ETX1153c; Mersanex; miconazole + nisin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator e-Therapeutics
  • Developer e-Therapeutics; Khandelwal Laboratories
  • Class Antibacterials; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors; Cell membrane modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections
  • Discontinued Clostridium difficile infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in India (Topical)
  • 16 Sep 2014 e-Therapeutics is looking for funding for ETX 1153c to resume development for Clostridium difficile infections
  • 23 May 2014 ETX 1153 is available for licensing as of 23 May 2014. http://www.etherapeutics.co.uk/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top